IN2014DN09554A - - Google Patents

Info

Publication number: IN2014DN09554A
Authority: IN; India
Prior art keywords: cyclohexyl; pharmaceutical compositions; relates; present; diabetes
Prior art date: 2012-05-17

Application number

Other languages

English (en)

Inventor

Lopez Maria Carmen Valcarce

Tung Fong

Original Assignee

Transtech Pharma Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-17

Filing date

2013-05-15

Publication date

2015-07-17

2013-05-15 Application filed by Transtech Pharma Llc filed Critical Transtech Pharma Llc

2015-07-17 Publication of IN2014DN09554A publication Critical patent/IN2014DN09554A/en

Links

239000008194 pharmaceutical composition Substances 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
HPGJSAAUJGAMLV-UHFFFAOYSA-N 2-[[2-[[cyclohexyl-(4-propoxycyclohexyl)carbamoyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetic acid Chemical compound C1CC(OCCC)CCC1N(C(=O)NC=1SC(SCC(O)=O)=CN=1)C1CCCCC1 HPGJSAAUJGAMLV-UHFFFAOYSA-N 0.000 abstract 1
HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 abstract 1
108010011459 Exenatide Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
229940127003 anti-diabetic drug Drugs 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
230000037396 body weight Effects 0.000 abstract 1
229960001519 exenatide Drugs 0.000 abstract 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
229960003105 metformin Drugs 0.000 abstract 1
MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 abstract 1
229960004034 sitagliptin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IN9554DEN2014 2012-05-17 2013-05-15 IN2014DN09554A (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261648110P	2012-05-17	2012-05-17
PCT/US2013/041076 WO2013173417A2 (en)	2012-05-17	2013-05-15	Glucokinase activator compositions for the treatment of diabetes

Publications (1)

Publication Number	Publication Date
IN2014DN09554A true IN2014DN09554A (pl)	2015-07-17

Family

ID=48576527

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN9554DEN2014 IN2014DN09554A (pl)	2012-05-17	2013-05-15

Country Status (16)

Country	Link
US (3)	US10004782B2 (pl)
EP (1)	EP2849776B1 (pl)
JP (1)	JP6234443B2 (pl)
KR (2)	KR20150013838A (pl)
CN (2)	CN118453592A (pl)
AU (2)	AU2013262895A1 (pl)
BR (1)	BR112014028622A2 (pl)
CA (1)	CA2872021C (pl)
EA (1)	EA201492109A1 (pl)
ES (1)	ES2878001T3 (pl)
HK (1)	HK1202458A1 (pl)
IL (1)	IL235484A0 (pl)
IN (1)	IN2014DN09554A (pl)
MX (1)	MX360304B (pl)
SG (2)	SG10201609644UA (pl)
WO (1)	WO2013173417A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2576524T (pt)	2010-05-26	2017-11-17	Vtv Therapeutics Llc	Resumo
IN2014DN09554A (pl) *	2012-05-17	2015-07-17	Transtech Pharma Llc
KR102408480B1 (ko)	2018-05-30	2022-06-10	이삼구	당뇨질환의 치료용 조성물
BR112020024269A2 (pt) *	2018-05-31	2021-02-23	Hua Medicine (Shanghai) Ltd.	combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos
CA3093025A1 (en)	2018-06-12	2019-12-19	Vtv Therapeutics Llc	Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
AU2020426356A1 (en) *	2020-01-31	2022-08-25	Hua Medicine (Shanghai) Ltd.	Treating treatment-resistant diabetes with glucokinase activator
US11872221B2 (en)	2020-01-31	2024-01-16	Hua Medicine (Shanghai) Ltd.	Treating untreated or treatment-resistant diabetes with glucokinase activator
US12391658B2 (en)	2020-02-18	2025-08-19	Vtv Therapeutics Llc	Sulfoxide and sulfone glucokinase activators and methods of use thereof
WO2021243646A1 (en) *	2020-06-04	2021-12-09	Hua Medicine (Shanghai) Ltd.	Glucokinase activator for treating diabetes with hepatic impairment
CA3185831A1 (en) *	2020-06-04	2021-12-09	Hua Medicine (Shanghai) Ltd.	Glucokinase activator for treating diabetes with renal impairment
US11857536B2 (en)	2020-06-04	2024-01-02	Hua Medicine (Shanghai) Ltd.	Glucokinase activator for treating diabetes with renal impairment
US12479808B2 (en)	2020-06-08	2025-11-25	Vtv Therapeutics Llc	Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
CA3181665A1 (en) *	2020-06-08	2021-12-16	Jing TENG	Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof
CN115350268B (zh) *	2022-08-24	2025-02-11	深圳青澜生物技术有限公司	一种用于治疗糖尿病的制剂、微针及其制备工艺

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT323195B (de)	1973-03-16	1975-06-25	Hurka Wilhelm	Verfahren zur herstellung neuer salze von biguaniden
FR2243684B1 (pl)	1973-09-19	1977-01-28	Semb
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5552160A (en)	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
US6794412B1 (en) *	1999-03-11	2004-09-21	Bristol-Myers Squibb Pharma Company	Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
SI1133312T1 (sl) *	1999-06-21	2008-02-29	Lilly Co Eli	Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
US6294546B1 (en) *	1999-08-30	2001-09-25	The Broad Of Trustees Of The Leland Stanford Junior University	Uses of diterpenoid triepoxides as an anti-proliferative agent
US6608038B2 (en) *	2000-03-15	2003-08-19	Novartis Ag	Methods and compositions for treatment of diabetes and related conditions via gene therapy
CA2744893A1 (en)	2002-06-27	2004-01-08	Novo Nordisk A/S	Aryl carbonyl derivatives as glucokinase activators
WO2004076420A1 (ja)	2003-02-26	2004-09-10	Banyu Pharmaceutical Co., Ltd.	ヘテロアリールカルバモイルベンゼン誘導体
JP4386035B2 (ja)	2003-07-14	2009-12-16	ソニー株式会社	情報提供システム、放送局特定サーバ、関連情報提供サーバ、コンテンツ配信サーバ、記録媒体販売サーバ及び情報提供方法
WO2005023766A1 (en)	2003-09-11	2005-03-17	Biocon Limited	Salt of atorvastatin with metformin
CN1910166B (zh) *	2004-01-06	2012-01-04	诺和诺德公司	杂芳基脲及其作为葡糖激酶活化剂的用途
BRPI0506662B8 (pt) *	2004-01-06	2021-05-25	Novo Nordisk As	compostos ativadores de glucoquinase
EP1758611A2 (en) *	2004-06-17	2007-03-07	Novo Nordisk A/S	Use of liver-selective glucokinase activators
WO2006110809A2 (en)	2005-04-12	2006-10-19	Elan Pharma International, Limited	Nanoparticulate lipase inhibitor formulations
US20100028439A1 (en)	2005-05-23	2010-02-04	Elan Pharma International Limited	Nanoparticulate stabilized anti-hypertensive compositions
CN101258137A (zh) *	2005-07-08	2008-09-03	诺沃-诺迪斯克有限公司	双环烷基脲葡糖激酶活化剂
JP2009500378A (ja)	2005-07-08	2009-01-08	ノボ・ノルデイスク・エー／エス	グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
JP2009500377A (ja)	2005-07-08	2009-01-08	ノボ・ノルデイスク・エー／エス	ジシクロアルキルウレア型グルコキナーゼ活性化剤
JP4960355B2 (ja)	2005-07-14	2012-06-27	ノボ・ノルデイスク・エー／エス	ウレア型グルコキナーゼ活性化剤
JP5419706B2 (ja)	2006-12-20	2014-02-19	タケダカリフォルニアインコーポレイテッド	グルコキナーゼアクチベーター
JP2010515701A (ja)	2007-01-09	2010-05-13	ノボ・ノルデイスク・エー／エス	ウレアグルコキナーゼアクチベーター
JP5513492B2 (ja)	2008-05-16	2014-06-04	タケダカリフォルニアインコーポレイテッド	グルコキナーゼ活性剤
EP2305737A4 (en)	2008-07-22	2015-03-04	Kureha Corp	PROCESS FOR PRODUCING POLYARYLENE SULFIDE HAVING REDUCED HALOGEN TERMINAL GROUP CONTENT
WO2010107610A1 (en) *	2009-03-17	2010-09-23	Merck Sharp & Dohme Corp.	Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds
AR076317A1 (es)	2009-04-16	2011-06-01	Taisho Pharmaceutical Co Ltd	Composiciones farmaceuticas que comprenden un compuesto de 1-tio-d-glucitol.
KR101190957B1 (ko)	2009-08-25	2012-10-15	한올바이오파마주식회사	메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
PT2576524T (pt)	2010-05-26	2017-11-17	Vtv Therapeutics Llc	Resumo
EP2392575A1 (en) *	2010-06-04	2011-12-07	LEK Pharmaceuticals d.d.	A novel synthetic approach to ß-aminobutyryl substituted compounds
IN2014DN09554A (pl)	2012-05-17	2015-07-17	Transtech Pharma Llc
HK1213197A1 (zh)	2013-03-04	2016-06-30	Vtv治疗有限责任公司	包括葡糖激酶活化劑的固體組合物及其製備和使用方法
CA2903433A1 (en)	2013-03-04	2014-09-12	Vtv Therapeutics Llc	Stable glucokinase activator compositions

2013
- 2013-05-15 IN IN9554DEN2014 patent/IN2014DN09554A/en unknown
- 2013-05-15 SG SG10201609644UA patent/SG10201609644UA/en unknown
- 2013-05-15 JP JP2015512779A patent/JP6234443B2/ja active Active
- 2013-05-15 EP EP13726933.8A patent/EP2849776B1/en active Active
- 2013-05-15 KR KR1020147035545A patent/KR20150013838A/ko not_active Ceased
- 2013-05-15 WO PCT/US2013/041076 patent/WO2013173417A2/en not_active Ceased
- 2013-05-15 MX MX2014013105A patent/MX360304B/es active IP Right Grant
- 2013-05-15 CN CN202410499223.0A patent/CN118453592A/zh active Pending
- 2013-05-15 CA CA2872021A patent/CA2872021C/en active Active
- 2013-05-15 EA EA201492109A patent/EA201492109A1/ru unknown
- 2013-05-15 ES ES13726933T patent/ES2878001T3/es active Active
- 2013-05-15 AU AU2013262895A patent/AU2013262895A1/en not_active Abandoned
- 2013-05-15 HK HK15103235.2A patent/HK1202458A1/xx unknown
- 2013-05-15 KR KR1020217006420A patent/KR102371364B1/ko active Active
- 2013-05-15 BR BR112014028622A patent/BR112014028622A2/pt not_active Application Discontinuation
- 2013-05-15 CN CN201380024802.XA patent/CN104349790A/zh active Pending
- 2013-05-15 SG SG11201406987UA patent/SG11201406987UA/en unknown
- 2013-11-05 US US14/071,976 patent/US10004782B2/en active Active
2014
- 2014-11-03 IL IL235484A patent/IL235484A0/en unknown
2017
- 2017-06-07 AU AU2017203835A patent/AU2017203835B2/en active Active
2018
- 2018-05-18 US US15/983,249 patent/US10588943B2/en active Active
2020
- 2020-01-16 US US16/744,956 patent/US10980861B2/en active Active

Also Published As

Publication number	Publication date
JP2015517525A (ja)	2015-06-22
AU2013262895A1 (en)	2014-11-13
BR112014028622A2 (pt)	2017-06-27
US10980861B2 (en)	2021-04-20
US10588943B2 (en)	2020-03-17
KR102371364B1 (ko)	2022-03-07
JP6234443B2 (ja)	2017-11-22
HK1202458A1 (en)	2015-10-02
EP2849776A2 (en)	2015-03-25
MX360304B (es)	2018-10-29
IL235484A0 (en)	2014-12-31
EA201492109A1 (ru)	2015-07-30
US20140066372A1 (en)	2014-03-06
ES2878001T3 (es)	2021-11-18
US20180311314A1 (en)	2018-11-01
CN104349790A (zh)	2015-02-11
KR20150013838A (ko)	2015-02-05
US20200138909A1 (en)	2020-05-07
WO2013173417A2 (en)	2013-11-21
CA2872021C (en)	2022-08-16
SG11201406987UA (en)	2014-12-30
KR20210027547A (ko)	2021-03-10
CA2872021A1 (en)	2013-11-21
AU2017203835B2 (en)	2018-11-22
WO2013173417A3 (en)	2014-02-20
SG10201609644UA (en)	2017-01-27
CN118453592A (zh)	2024-08-09
US10004782B2 (en)	2018-06-26
AU2017203835A1 (en)	2017-06-22
MX2014013105A (es)	2015-04-08
EP2849776B1 (en)	2021-04-21

Publication	Publication Date	Title
MX2014013105A (es)	2015-04-08	Composiciones de activador de glucocinasa para el tratamiento de la diabetes.
BR112013029256A2 (pt)	2016-11-29	"combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
PH12015502042A1 (en)	2016-01-18	Use of linagliptin in cardio-and renoprotective antidiabetic therapy
BR112015005972A2 (pt)	2017-07-04	derivados do tipo amida de ácido benzoimidazol-carboxílico como moduladores do receptor apj
MX2014015423A (es)	2015-04-09	Analogos de peptido de exedina-4.
BR112015013809A2 (pt)	2017-11-14	derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
EA201892383A1 (ru)	2019-03-29	Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
UA117103C2 (uk)	2018-06-25	Сполука, яка має активність агоніста глюкагону
CL2015001241A1 (es)	2015-08-14	Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
MX362527B (es)	2019-01-23	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
EA201490004A1 (ru)	2014-09-30	Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MY167234A (en)	2018-08-14	Novel glucagon analogues
WO2015106269A8 (en)	2016-08-18	Rapid action insulin formulations and pharmaceutical delivery systems
BR112014016810A2 (pt)	2017-06-13	composições e métodos para tratamento de distúrbios metabólicos
EA201490377A1 (ru)	2014-11-28	Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
UA113849C2 (xx)	2017-03-27	Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
EA201201617A1 (ru)	2013-04-30	Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
MY165122A (en)	2018-02-28	Dipeptidyl peptidase-iv (dppiv) inhibitory peptide compound, composition containing the same, and production method for the same
JOP20130256B1 (ar)	2021-08-17	مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
JP2017502074A5 (pl)	2017-10-19
MX2016007989A (es)	2016-09-13	Derivados de oxindol, preparacion de los mismos y uso terapeutico en el tratamiento de enfermedades relacionadas con ampk.
EA201791611A1 (ru)	2017-11-30	Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
MX2020001434A (es)	2020-03-20	Analogos de insulina acilados novedosos y usos de estos.
IN2013MU03847A (pl)	2015-07-24
SG10201908089VA (en)	2019-10-30	Novel dosing regimens of celgosivir for the treatment of dengue